by Christina Black | Nov 9, 2017 | News
Important Achievements Validate OmniSeq’s High Quality Laboratory Practices and Immune Report Card Assay Buffalo, NY – NOVEMBER 9, 2017 – OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it received...
by Christina Black | Jun 14, 2017 | News
BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) — OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling test designed to help oncologists select the best mono and...
by Christina Black | Jun 27, 2016 | News
BUFFALO, NY – June 28, 2016 – OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its OmniSeq ComprehensiveSM panel, a 144 gene, pan-cancer, next-generation sequencing (NGS) tumor...
